Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin

Author： Choi Chel   Kim Min   Park Jin-Young   Yoon Aera   Kim Ha-Jeong   Lee Yoo-Young   Kim Tae-Joong   Lee Jeong-Won   Kim Byoung-Gie   Bae Duk-Soo  

Publisher： Springer Publishing Company

ISSN： 0941-4355

Source： Supportive Care in Cancer, Vol.22, Iss.5, 2014-05, pp. : 1181-1187

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer

By Navari Rudolph M  

Future Oncology, Vol. 6, Iss. 7, 2010-07 ,pp. : 1073-1084

Future Medicine

Access to resources Recommend Favorite

Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: Accumulating evidence for synergy, efficacy, and safety

By Pentheroudakis G.   Razis E.   Athanassiadis A.   Pavlidis N.   Fountzilas G.  

Medical Oncology, Vol. 23, Iss. 2, 2006-06 ,pp. : 147-160

Humana Press, Inc

Access to resources Recommend Favorite

Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer

By Murakami Michiyasu   Hashimoto Hiroki   Yamaguchi Kyohei   Yamaguchi Ikuko   Senba Shozo   Siraishi Takeshi  

Supportive Care in Cancer, Vol. 22, Iss. 4, 2014-04 ,pp. : 905-909

Springer Publishing Company

Access to resources Recommend Favorite

Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy

By Molassiotis Alex   Nguyen Allison Martin   Rittenberg Cynthia N   Makalinao Alex   Carides Alexandra  

Future Oncology, Vol. 9, Iss. 10, 2013-10 ,pp. : 1443-1450

Future Medicine

Access to resources Recommend Favorite

Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

By Saito H.   Yoshizawa H.   Yoshimori K.   Katakami N.   Katsumata N.   Kawahara M.   Eguchi K.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1067-1073

Oxford University Press

Access to resources Recommend Favorite